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Abstract
Aim—To investigate the presence of mem-
brane “flip flop” in ischaemic human
myocardium, we assessed depositions of
apolipoprotein H (apoH; â2-glycoprotein
1) in ischaemic myocardium. Serum pro-
tein apoH can bind to negatively charged
phospholipids and can also inhibit blood
coagulation in vitro.We hypothesised that,
because of its aYnity for phosphatidyl
serine, apoH might bind to “flip flopped”
cells and would therefore be useful as a
marker for membrane flip flop in vivo.
Methods—Myocardial tissue specimens
were obtained from patients who had died
within 14 days of acute myocardial infarc-
tion.
Results—Immunohistochemical analysis
of these specimens revealed that apoH was
selectively deposited in infarcted areas of
human myocardium of at least one day’s
duration. Depositions of apoH were not
found in non-ischaemic myocardial tissue
samples obtained from patients who died
from other (extracardial) causes. In vitro
experiments with the human leukaemia T
cell line Jurkat, subjected to apoptosis by
etoposide, showed that apoH was bound to
the membrane of apoptotic cells. How-
ever, these experiments also indicated that
flip flop itself is not suYcient for apoH
binding. In addition, Jurkat cells that
bound apoH were positive for activated
complement complexes, as was also found
in the human heart.
Conclusions—These results suggest that
apoH is involved in the inflammatory
processes that occur in ischaemic myo-
cardium.
(J Clin Pathol 2000;53:863–867)
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Apolipoprotein H (apoH; â2-glycoprotein 1) is
a 50 kDa phospholipid binding serum protein
that preferentially binds to negatively charged
phospholipids such as phosphatidyl serine
(PS).1 2 Because of this property, apoH might
inhibit blood coagulation and ADP dependent
platelet aggregation, at least in vitro. Its precise
physiological role remains to be elucidated.3
Chonn et al found that the fast clearance of PS
containing liposomes by the liver in mice is
mediated via plasma derived apoH, suggesting
that this protein might have a role in removing
PS containing microvesicles.4
Recently, we have shown co-deposition of
complement with the acute phase protein C
reactive protein (CRP) in infarcted sites of
human myocardium.5 The ligand for CRP in
infarcted myocardium, however, remains to be
established. One possibility6 is that binding
sites for CRP are generated in cells that have
undergone so called “flip flop”.7 In normal
cells, various phospholipids are asymmetrically
distributed between the inner and outer leaflet
of the membrane, PS being mainly located in
the inner leaflet. In damaged cells (ischaemic,
apoptotic, or necrotic cells) phospholipids of
the inner and outer leaflet exchange, a
phenomenon known as flip flop,8 9 leading to
the exposure of PS in the outer leaflet. We
hypothesised that because of its aYnity for PS,
apoH could be used as an in vivo marker for
these “flip flopped” cells. In our present study
we tested this hypothesis and searched for
apoH depositions in the infarcted myocar-
dium, in relation to those of activated comple-
ment.
Patients, materials, and methods
PATIENTS
Patients, referred to the department of pathol-
ogy for necropsy, were included in this study
when at necropsy they showed signs of a recently
developed acute myocardial infarction; that is,
decreased lactate dehydrogenase (LD) staining
(decolouration) of the aVected myocardium.
Most of the patients had participated in earlier
studies on the involvement of CRP and comple-
ment in infarcted myocardium.5 Our study was
approved by the ethics committee of the Free
University Hospital Amsterdam.
PROCESSING OF TISSUE SPECIMENS
Myocardial tissue specimens were obtained
from the infarcted as well as from adjacent
sites. These latter sites showed normal LD
staining patterns and were studied as internal
controls. Before being prepared as cryosec-
tions, the tissue specimens were stored at
−196°C (liquid N2). The glass slides used for
microscopy were pretreated with 0.1% poly-L-
lysine (Sigma Chemical Company, St Louis,
Missouri, USA) to enhance the adherence of
the frozen tissue sections.
ANTIBODIES
We used a monoclonal antibody (C3-9; IgG-1
subclass) against activated complement factor
C3 that has been used previously for immuno-
histochemical studies.5 Cof23, directed against
apoH, was a gift of Dr Koike (Department of
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Medicine II, Hokkaido University School of
Medicine, Sapporo, Japan). Polyclonal rabbit
antihuman apoH/34, was obtained by immu-
nising rabbits with purified apoH (Department
of AutoImmune Diseases, CLB, Sanguin
Blood Supply Foundation, The Netherlands).
For FACS analysis, fluorescein isothiocy-
anate (FITC) conjugated annexin V (Boe-
hringer Ingelheim, Heidelberg, Germany) and
phycoerythrin (PE) conjugated streptavidin
(Amersham International, Amersham, UK)
were used.
Biotinylation of monoclonal and polyclonal
antibodies using L-C-biotin-N-hydroxi-
succimide ester (Pierce Chemical Co., Rock-
ford, IL) was performed according to the
manufacturer’s instructions.
FACS ANALYSIS
The human leukaemia T cell line Jurkat was
maintained in Iscove’s modified Dulbecco’s
medium (IMDM) (Gibco, Grand Island, New
York, USA) supplemented with 5% (vol/vol)
fetal calf serum (FCS), 100 U/ml penicillin
(Gibco), 100 µg/ml streptomycin (Gibco),
50 µM 2-mercaptoethanol, and 20 µg/ml
human transferrin (Sigma) (culture medium)
at 37°C in a humid atmosphere and 5% CO2.
Apoptosis was induced in the Jurkat cells by
incubation with 25 µM etoposide (Sigma)
overnight. The cells were then separated from
the medium by centrifugation at 800 ×g for six
minutes, resuspended in IMDM (no FCS) in a
96 well roundbottom plate (100 µl/well,
200 000 cells/well), and washed once with
IMDM. Thereafter, cells were incubated with
serum (or purified apoH) diluted in IMDM
(50 µl/well), for 30 minutes at 37°C. After
washing four times with BB (1.19 g Hepes,
4.4 g NaCl, 0.19 g KCl, 0.10 g CaCl2, 0.1 g
MgCl2 in 500 ml, pH 7.4) and BA (0.5% (wt/
vol) bovine serum albumin (BSA) (Boehringer
Mannheim), 0.02% (wt/vol) azide), bioti-
nylated anti-apoH antibodies (5 µg/ml in buVer
BB-BA, 50 µl/well) or anti-C3 monoclonal
antibody (C3-9) were added to the cells for 30
minutes at 4°C. After three washes with BB-BA
buVer, a mixture of PE labelled streptavidin
(Becton Dickinson, San Jose, California, USA)
and FITC labelled annexin V (Boehringer
Ingelheim), diluted 1/200 and 1/2000 in
BB-BA buVer, respectively, was added to the
cells (final volume 50 µl/well). After 20 minutes
of incubation at 4°C in the dark, the cells were
washed three times with BB-BA. Finally, cells
were resuspended in 100 µl BB-BA in epics-
tubes and analysed on a FACScan (Becton
Dickinson, San Jose, California, USA).
IMMUNOHISTOCHEMISTRY
Frozen sections (4 µm thick) were mounted on
to glass slides, dried for one hour by exposure
to air, and fixed in acetone (“Baker analysed
reagent”; Mallinckrodt Baker BV, Deventer,
Holland). The slides were incubated at room
temperature for 10 minutes with normal rabbit
serum (Dakopatts A/S, Glostrup, Denmark)
and diluted 1/50 in phosphate buVered saline
(PBS) containing 1% (wt/vol) BSA (PBS-BSA)
after rinsing in PBS. Incubation of the slides
with specific antibody solutions was performed
for 60 minutes at room temperature (C3-9
diluted 1/1000 in PBS-BSA; biotinylated anti-
apoH polyclonal antibody diluted 1/500;
monoclonal antibody against apoH diluted
1/400). In control experiments, similar incuba-
tions were performed with irrelevant control
monoclonal antibodies: IgG1 and mouse my-
eloma protein, MOPC (Cappel, Organon
Teknika, Turnhout, Belgium).
The slides incubated with antibodies against
complement were washed for 30 minutes with
PBS and incubated with horseradish peroxi-
dase conjugated rabbit antimouse immuno-
globulins (RaM-HRP; Dakopatts A/S), diluted
1/25 in PBS-BSA. The slides incubated with
biotinylated anti-apoH monoclonal or polyclo-
nal antibodies were washed for 30 minutes and
incubated with streptavidin horseradish peroxi-
dase conjugates (Dakopatts), diluted 1/500 in
PBS-BSA for one hour. Thereafter, the slides
were washed again in PBS and incubated for
four minutes in 0.5 mg/ml 3,3'-
diaminobenzidinetetrahydrochloride (DAB;
Sigma) in PBS, pH 7.4, containing 0.01% (vol/
vol) H2O2. The slides were then washed again,
counterstained with haematoxylin for 40 sec-
onds, dehydrated, cleared, and finally
mounted.
Microscopic criteria10 11 were used to estimate
infarct duration in all myocardial tissue speci-
mens. Jeopardised fibres were characterised by
the intensity of eosinophilic staining of involved
myofibres, loss of nuclei and cross striation,
polymorphonuclear neutrophil and lymphocyte
infiltration, and fibrosis. However, because
morphological judgement is more reliable in
paraffin wax embedded slides, corresponding
paraYn wax embedded tissue slides were also
made, to confirm the determination of jeopard-
ised versus non-jeopardised tissue. Two inde-
pendent investigators (HWMN, WKL) each
judged and scored all slides for infarct duration
and anatomical localisation of specific antibody
as visualised by immunohistochemical staining.
Anatomical localisations examined were myofi-
bre (membrane, cytoplasm, cross striations)
and bloodvessel elements. For the final scoring
results, a consensus was achieved by the two
investigators.
Results
PATIENTS
Myocardial tissue specimens were obtained
from 17 patients who had died after acute
myocardial infartion as confirmed by necropsy
performed within 24 hours after death (table
1). Specimens were obtained from the inf-
arcted as well as from the unaVected myocar-
dial tissue. The infarct age, assessed by micro-
Table 1 Duration of infarctions in the patients included
Infarction age Number of patients
< 12 hours 3
> 12 to < 24 hours 1
1–3 days 4
3–5 days 2
5–9 days 3
9–14 days 4
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scopical criteria,10 11 varied from less than 12
hours to more than 2 weeks.
LOCALISATION OF ACTIVATED COMPLEMENT AND
apoH IN INFARCTED MYOCARDIUM
As shown recently, complement was localised
in infarcted sites of human myocardium.5 Apo-
H, as detected by the biotinylated monoclonal
antibody, was found in the same parts that
stained positive for complement (fig 1).
Notably, staining for apoH was most intense at
the plasma membrane of cardiomyocytes.
Cytoplasmatic localisation of apoH was also
found, although staining for apoH in the cyto-
plasm was clearly less than that of the plasma
membrane. Some staining of cross striations
was also found (fig 2). In larger infarcts, the
border zone appeared to stain more intensively
for apoH than the centre of the infarcted
region.
Similar to complement, apoH was not
detected in infarctions of less then 24 hours
duration. Furthermore, apoH was not found
on endothelium, in contrast to complement.5
Similar staining results were obtained when a
biotinylated rabbit polyclonal antibody was
used against apoH (fig 3).
Staining of the myocardial tissue specimens
with irrelevant control antibodies yielded
negative results. In addition, internal
controls—specimens taken from non-infarcted
sites of the myocardium of the same patient—
did not stain for C3 or apoH. Furthermore,
myocardial tissue specimens from an immature
child who died in utero at an amenorrhoea
duration of 22 weeks (these specimens were
taken to represent a pure, non-ischaemic myo-
cardial control) did not stain for C3 or apoH,
and neither did an old infarction (> 1 year old).
Unfortunately, immunohistochemical stud-
ies have the limitation that the well known
marker of membrane flip flop, annexin V, can-
not be used reliably in tissue slides of the heart.
For this reason, we performed in vitro studies
using Jurkat cells. These cells were incubated
with etoposide overnight, which causes them to
die as a result of apoptosis.12 Subsequently, the
cells were incubated with anti-apoH or anti-
C3. The flip flop phenomenon was assessed by
staining for annexin V. The cells that were
annexin V negative did not bind apoH (table
2), whereas annexin V positive cells did.
Recently Manfredi et al have shown that Jurkat
cells, positive for annexin V, stained for
apoH.13 14 However, when we characterised
these cells in more detail, it appeared that only
cells that also stained with propidium iodide
Figure 1 (A) Immunohistochemical localisation of the
activated complement component C3 (monoclonal antibody
C3-9) and (B) apolipoprotein H (biotinylated monoclonal
antibody) in infarcted myocardium (J, jeopardised; N,
normal). Specimens were from a patient with an infarction
of five to nine days’ duration. The frozen tissue sections
shown were from the same myocardial infarction site
(magnification, ×100).
Figure 2 Positive staining of myofibre elements
(sarcolemma, (A) cytoplasm, and (B) cross striation
(arrows)) in infarcted myocardium for apolipoprotein H
(biotinylated monoclonal antibody; magnification, ×630).
The specimen is from a patient with an infarction of one to
three days’ duration.
Figure 3 Immunohistochemical localisation of
apolipoprotein H (biotinylated polyclonal antibody) in
infarcted myocardium. Specimens were from a patient with
infarction of five to nine days’ duration (magnification,
×630).
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(and thus were beyond the early phase of
apoptosis as characterised by the flip flop phe-
nomenon) bound apoH. This indicates that
staining for apoH is not discriminative in
detecting cells that only underwent flip flop of
the membrane. However, similar to the
immunohistochemical staining results in the
heart, apoH positive cells also bound comple-
ment, suggesting a role of both mediators in the
inflammatory mediated process of cell death.
Discussion
The precise mechanisms contributing to myo-
cardial cell death in the human myocardium
after infarction are still not fully understood.
We have hypothesised that in jeopardised myo-
cardium the membrane of cardiomyocytes
might become perturbed, thereby becoming a
target for acute phase proteins such as serum
phospholipase A2 and CRP.6 This would result
in fixation of CRP to the cells and the
subsequent activation of complement.6 Indeed,
colocalisation of complement and CRP in
jeopardised human myocardium was recently
demonstrated, supporting this hypothetical
mechanism.5
Perturbation of the cell membrane involves
an exchange of phospholipids of the inner and
outer leaflets, resulting in flip flop of the mem-
brane. As a consequence of this process, cells
expose PS in the outer leaflet. Flip flop of cell
membranes in vivo is diYcult to demonstrate.
It has been shown that in vitro apoH binds to
PS.15 Because of this property, apoH deposition
in tissues may reflect flip flop of membranes in
vivo. In our present study, we indeed found that
apoH is localised to jeopardised human
myocardium. Moreover, apoH in particular
appeared to bind to the membranes of cardio-
myocytes, supporting its supposed function as
a marker for membrane flip flop. However, in
vitro experiments in human leukaemia T cell
Jurkat cells indicate that flip flop itself is not
suYcient for apoH binding.
In addition to binding to PS, apoH might
also bind to cardiolipin.16–18 Cardiolipin is a
constituent of the inner19 20 and outer mito-
chondrial membrane.21 Thus, cardiolipin
might also serve as a binding site for apoH.
This could explain the cytosolic localisation of
apoH that we saw in a few of the infarctions.
The identity of the ligands for apoH on (apop-
totic) cells is currently under investigation.
In addition, another apolipoprotein, apo-
liprotein J (clustrin) has been found to be colo-
calised in ischaemic human hearts together
with complement membrane attack complex
(MAC).22 It has been suggested that apolipo-
protein J might be involved in the clearance of
damaged and necrotic tissue, together with
MAC. A similar role might be played by apoH,
especially because the clearance of liposomes
by the liver in mice is in part mediated by
plasma derived apoH. Interestingly, after inter-
action with serum, liposomes not only become
positive for apoH but also for complement.4 In
the human myocardium and in in vitro experi-
ments with Jurkat cells, we have shown
colocalisation of activated complement and
apoH. This raises the possibility that apoH,
bound to cells, might trigger or enhance com-
plement activation, directly or indirectly via
CRP–ligand complexes.
In conclusion, for the first time we have
shown that apoH is localised in infarcted
human myocardium to areas that also contain
CRP and activated complement.5 We therefore
hypothesise that apart from complement, CRP,
and apolipoprotein J, apoH is a new player in
the inflammatory changes ensuing in infarcted
myocardium.
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Correspondence
MPO-ANCA may produce a
combination of P-ANCA and atypical
cytoplasmic ANCA indirect
immunofluorescent patterns on certain
ethanol fixed neutrophil substrates
The P-ANCA pattern is defined as perinu-
clear indirect immunofluorescent (IIF) stain-
ing on ethanol fixed normal human
neutrophils.1–3 This pattern is an artefact of
ethanol fixation, dependent on the redistribu-
tion of certain cationic neutrophil granule
proteins (such as myeloperoxidase (MPO),
lactoferrin, and lysozyme) around the nega-
tively charged nuclear membrane.1 2 However,
certain MPO-ANCA can produce cytoplas-
mic rather than perinuclear IIF staining,4 pos-
sibly related to a subpopulation of epitopes on
MPO that do not redistribute with ethanol
fixation.2 We now report that MPO-ANCA
positive sera may produce a combination of
P-ANCA and atypical cytoplasmic5 ANCA
IIF patterns on certain ethanol fixed neutro-
phil substrates, potentially leading to interpre-
tative and diagnostic diYculties.
Sera from six patients with biopsy con-
firmed microscopic polyangiitis (at diVerent
stages of disease activity) were selected
because of initial diYculties in the interpret-
ation of their IIF patterns on ethanol fixed
neutrophil slides from Inova Diagnostics
(San Diego, California, USA). All six sera
were MPO-ANCA positive and proteinase
3-ANCA (PR3-ANCA) negative by the
corresponding ORGenTec (Mainz, Ger-
many) enzyme linked immunosorbent assay
(ELISA). PR3-ANCA positive serum from a
patient with biopsy confirmed Wegener’s
granulomatosis was also tested. To establish
whether other ANCA antigen specificities
were present, all sera were tested on the
ORGenTec ANCA Combi-kit® ELISA con-
taining proteinase-3, MPO, lactoferrin,
elastase, cathepsin G, lysozyme, and
bactericidal/permeability increasing protein
(BPI). IIF was then repeated on all sera on
two separate occasions using in house (kindly
supplied by the Division of Immunology,
Royal Brisbane Hospital) and two commer-
cial (Inova Diagnostics (diVerent batch) and
Medical and Biological Laboratories (MBL,
Nagoya, Japan)) ethanol fixed neutrophil
slides. The IIF staining patterns and end
point titres were determined by consensus.
Table 1 summarised the results. In four of
the six sera, no reactivity other than MPO-
ANCA was detected using the ANCA
Combi-kit ELISA. Of the other two sera, one
also contained lactoferrin-ANCA and the
other lysozyme-ANCA. Nevertheless, in ad-
dition to P-ANCA staining, atypical cytoplas-
mic staining was consistently produced by all
six MPO-ANCA sera on the Inova slides, but
not on the MBL or in house slides. These
findings were reproducible on two diVerent
batches of neutrophil slides from the former
manufacturer.
Our small study demonstrates that sera
containing MPO-ANCA may produce a
combination of P-ANCA and atypical cyto-
plasmic IIF patterns on certain ethanol fixed
neutrophil substrates. The recent Inter-
national Consensus Statement recommends
that such combined patterns be reported as
“atypical ANCA”.3 Because atypical ANCA
are not strongly associated with microscopic
polyangiitis or Wegener’s granulomatosis,3 an
atypical ANCA IIF report on these sera could
potentially erroneously lead the requesting
clinician away from the correct diagnosis.
However, in all six sera, the positive MPO-
ANCA ELISA result would hopefully redi-
rect attention towards a possible diagnosis of
systemic necrotising vasculitis.
We have subsequently found that these
combined IIF patterns do not occur with all
MPO-ANCA positive sera on the Inova
slides, and thus speculate that the phenom-
enon might be caused by factors in the etha-
nol fixation conditions of these slides result-
ing in the diVerential redistribution of
diVerent MPO epitopes. Therefore, we rec-
ommend that laboratories using this brand
(and possibly other commercial brands) of
ethanol fixed neutrophil slides be aware of
this phenomenon, and consider repeating any
sera producing such combined “atypical
ANCA” IIF patterns on alternative ethanol
fixed neutrophil substrates to clarify their
“true” IIF pattern. Furthermore, antigen
specific ELISA testing for MPO-ANCA and
PR3-ANCA should also be performed on all
such sera3 because combining IIF and ELISA
in ANCA testing improves overall diagnostic
specificity/predictive value compared with
using either test alone.6
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High prevalence of serum markers of
coeliac disease in patients with chronic
fatigue syndrome
There has been recent interest in the
possibility that undiagnosed coeliac disease
(CD) might be the cause of diverse clinical
symptoms, most particularly “tired all the
time”.1 A recent study reported a prevalence
of three in 100 cases in a primary care
environment in which samples were taken
from patients with a range of symptoms and
signs.2 The second most frequent symptom
reported by the endomysial antibody (EMA)
positive patients was “being tired all the
time”. We decided to examine the prevalence
of EMA in patients attending our tertiary
referral centre with the diagnosis of chronic
fatigue syndrome (CFS).
We tested serum from 100 consecutive
patients (47 men, 53 women; median age, 40
years; range, 18–57) referred to our specialist
clinic and satisfying the standard CDC crite-
ria for a diagnosis of CFS, and from 100
healthy control subjects (45 men, 55 women;
median age, 40 years; range, 18–68) who
were blood donors at the South East Thames
Blood Transfusion Service. The CFS sam-
ples had been stored as part of other studies,
and were analysed retrospectively. EMA of
the IgA class were detected by indirect
immunofluorescence (IF) using cryostat sec-
tions of distal primate oesophagus as sub-
strate (Binding Site, Birmingham, UK). Posi-
tive samples were confirmed using an enzyme
linked immunosorbant assay (ELISA) for the
detection of antitissue transglutaminase anti-
bodies3 (Menarini Diagnostics, Wokingham,
Table 1 MPO-ANCA and PR3-ANCA ELISA,ANCA Combi-kit® ELISA, and ANCA IIF
results
Sera
MPO-ANCA and
PR3-ANCA IgG
ELISA (U/ml)
ANCA Combi-kit IgG
ELISA (OD ratio)
IIF staining pattern (titre) on ethanol fixed neutrophils
using polyclonal FITC conjugated antihuman IgG
Inova Diagnostics MBL
In house
cytospin
1 MPO positive (58) MPO (6.4) P (1/160) P (1/160) P (1/160)
PR3 negative Atypical cytoplasmic (1/160)
2 MPO positive (61) MPO (2.9) P (1/160) P (1/160) P (1/160)
PR3 negative Atypical cytoplasmic (1/10)
3 MPO positive (8) MPO (1.6) P (1/40) P (1/160) P (1/160)
PR3 negative Atypical cytoplasmic (1/40)
4 MPO positive (6) MPO (1.3) P (1/10) P (1/40) P (1/40)
PR3 negative Atypical cytoplasmic (1/40)
5 MPO positive (>100) MPO (9.1) P (1/160) P (1/640) P (1/160)
PR3 negative Lysozyme (1.7) Atypical cytoplasmic (1/160)
6 MPO positive (36) MPO (5.2) P (1/160) P (1/160) P (1/160)
PR3 negative Lactoferrin (1.1) Atypical cytoplasmic (1/10)
7 MPO negative PR3 (6.44) C (1/40) C (1/40) C (1/40)
PR3 positive (53)
ORGenTec MPO-ANCA and PR3-ANCA IgG ELISA: positive, >5 U/ml; negative,<5 U/ml.
ORGenTec ANCA Combi-kit® IgG ELISA OD ratio: positive, >1; negative, <1 (only positive results
shown).
IIF staining pattern: C, classic granular cytoplasmic IIF staining with central/interlobular accentuation.
P, perinuclear.
Sera 1–6 were from patients with biopsy confirmed microscopic polyangiitis.
Serum 7 was from a patient with biopsy confirmed Wegener’s granulomatosis.
ANCA, antineutrophil cytoplasmic antibody; ELISA, enzyme linked immunosorbent assay; FITC,
fluorescein isothiocyanate; IIF, indirect immunofluorescence; MPO, myeloperoxidase; OD, optical density;
PR3, proteinase 3.
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UK), tissue transglutaminase being the auto-
antigen responsible for the IF pattern of
EMA. To exclude selective IgA deficiency,
serum IgA concentrations were measured by
laser nephelometry using specific antisera
according to the manufacturer’s instructions
(Behring Laser Nephelometer II; Dade Be-
hring, Dortmund, Germany).
Two of the 100 CFS samples were positive
for EMA using IF, and this was confirmed by
ELISA, but none of the 100 control samples
was positive. None of the subjects had selec-
tive IgA deficiency. Mean (SD) serum IgA
concentrations among patients with CFS
were 2.1 g/litre (0.98). Neither of the positive
cases, both women aged 27 and 54, had
reported symptoms typical of CD, although
one had a history of constipation. Routine
blood tests including serum proteins and full
blood count were normal, and both had been
seen by consultant physicians before referral.
Both had histories of hypothyroidism, were
taking long term thyroxine, and were cur-
rently euthyroid. Before the diagnosis of CD
was made retrospectively, both had received
cognitive behaviour therapy (CBT), a stand-
ard treatment for CFS. In both cases, CBT
led to a substantial improvement in the qual-
ity of life and physical activity, but neither
patient was symptom free at the end of treat-
ment or at six months follow up. In both
cases, CD was subsequently confirmed on
jejunal biopsy after the retrospective identifi-
cation.
In general, it remains true that although a
wide range of physical illnesses can be misdi-
agnosed as CFS (see Wessely et al for
review4), in practice this is uncommon. In
particular, if basic physical examination,
investigations, and history are unremarkable,
misdiagnosis of CFS and other physical
illnesses is very unusual. Until now there have
only been two reports concerning three cases
of CD being misdiagnosed as CFS.5 6
However, there is now evidence from
primary care of a surprisingly high frequency
of unsuspected positive EMA tests in people
with non-specific symptoms and a suggestion
that a higher index of suspicion is needed
when assessing such patients.2 We now
extend that observation to our CFS clinic.
Indeed, given our prevalence of 2%, and the
fact that there is a treatment for CD, we now
suggest that screening for CD should be
added to the relatively short list of mandatory
investigations in suspected cases of CFS.
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Correction
Niessen HWM, Lagrand WK, Rensink
HJAM, et al. Apolipotrotein H, a new media-
tor in the inflammatory changes ensuing in
jeopardised human myocardium. J Clin
Pathol 2000;53:863–7.
C Visser (Department of Cardiology, Free
University Hospital, 1007 MB Amsterdam,
The Netherlands) was mistakenly ommitted
from the list of authors of this paper. The
journal apologises for any inconvenience that
this may have caused.
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